Cipla receives final approval for the generic version of Somatuline Depot Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Subscribe To Our Newsletter & Stay Updated